Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2023 Sep 22:2023.05.12.23289807.
doi: 10.1101/2023.05.12.23289807.

Systematic Review of Treatment of Beta-Cell Monogenic Diabetes

Rochelle N Naylor  1 , Kashyap A Patel  2 , Jarno L T Kettunen  3 , Jonna M E Männistö  4 , Julie Støy  5 , Jacques Beltrand  6 , Michel Polak  7 ; ADA/EASD PMDI; Tina Vilsbøll  8 , Siri A W Greeley  1 , Andrew T Hattersley  2 , Tiinamaija Tuomi  9
Affiliations

Systematic Review of Treatment of Beta-Cell Monogenic Diabetes

Rochelle N Naylor et al. medRxiv. .

Update in

Abstract

Background: Beta-cell monogenic forms of diabetes are the area of diabetes care with the strongest support for precision medicine. We reviewed treatment of hyperglycemia in GCK-related hyperglycemia, HNF1A-HNF4A- and HNF1B-diabetes, Mitochondrial diabetes (MD) due to m.3243A>G variant, 6q24-transient neonatal diabetes (TND) and SLC19A2-diabetes.

Methods: Systematic reviews with data from PubMed, MEDLINE and Embase were performed for the different subtypes. Individual and group level data was extracted for glycemic outcomes in individuals with genetically confirmed monogenic diabetes.

Results: 147 studies met inclusion criteria with only six experimental studies and the rest being single case reports or cohort studies. Most studies had moderate or serious risk of bias.For GCK-related hyperglycemia, six studies (N=35) showed no deterioration in HbA1c on discontinuing glucose lowering therapy. A randomized trial (n=18 per group) showed that sulfonylureas (SU) were more effective in HNF1A-diabetes than in type 2 diabetes, and cohort and case studies supported SU effectiveness in lowering HbA1c. Two crossover trials (n=15 and n=16) suggested glinides and GLP-1 receptor agonists might be used in place of SU. Evidence for HNF4A-diabetes was limited. While some patients with HNF1B-diabetes (n=301) and MD (n=250) were treated with oral agents, most were on insulin. There was some support for the use of oral agents after relapse in 6q24-TND, and for thiamine improving glycemic control and reducing insulin requirement in SLC19A2-diabetes (less than half achieved insulin-independency).

Conclusion: There is limited evidence to guide the treatment in monogenic diabetes with most studies being non-randomized and small. The data supports: no treatment in GCK-related hyperglycemia; SU for HNF1A-diabetes. Further evidence is needed to examine the optimum treatment in monogenic subtypes.

Keywords: 6q24; GCK; Genetics; HNF1A; HNF1B; HNF4A; MODY; Mitochondrial diabetes; Monogenic Diabetes; Neonatal Diabetes; Precision Medicine; SLC19A2; Syndromic Diabetes; m.3243A>G.

PubMed Disclaimer

Conflict of interest statement

Authors’ declaration of personal interests JK has received lecture fees from NovoNordisk, international conference costs covered by Medtronic, AstraZeneca and NovoNordisk; MP has been the scientific advisor for the AMGLIDIA (glibenclamide suspension) development; TV has served on scientific advisory panels, been part of speaker’s bureaus, and served as a consultant to, and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gilead, GSK, Mundipharma, MSD/Merck, Novo Nordisk, Sanofi, and Sun Pharmaceuticals. RNN, KAP, JMEM, JS, JB, SAWG, ATH, TT report no conflicts of interest.

Figures

Figure 1.
Figure 1.
PRISMA search summary for GCK-, HNF1A- and HNF4A MODY
Figure 2.
Figure 2.
PRISMA search summary for HNF1B-MODY and mitochondrial diabetes
Figure 3.
Figure 3.
PRISMA search summary for 6q24-related transient neonatal diabetes
Figure 4.
Figure 4.
PRISMA search summary for SLC19A2-diabetes
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Semple RK, Patel KA, Auh S, ADA/EASD PMDI, Brown RJ. Systematic review of genotype-stratified treatment for monogenic insulin resistance. medRxiv. 10.1101/2023.04.17.23288671 - DOI
    1. Riddle MC, Philipson LH, Rich SS, Carlsson A, Franks PW, Greeley SAW, Nolan JJ, Pearson ER, Zeitler PS, Hattersley AT. Monogenic Diabetes: From Genetic Insights to Population-Based Precision in Care. Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes Care. 2020. Dec;43(12):3117–3128. doi: 10.2337/dci20-0065. - DOI - PMC - PubMed
    1. Chung WK, Erion K, Florez JC, Hattersley AT, Hivert MF, Lee CG, McCarthy MI, Nolan JJ, Norris JM, Pearson ER, Philipson L, McElvaine AT, Cefalu WT, Rich SS, Franks PW. Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020. Jul;43(7):1617–1635. doi: 10.2337/dci20-0022. - DOI - PMC - PubMed
    1. Greeley SAW, Polak M, Njølstad PR, Barbetti F, Williams R, Castano L, Raile K, Chi DV, Habeb A, Hattersley AT, Codner E. ISPAD Clinical Practice Consensus Guidelines 2022: The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2022. Dec;23(8):1188–1211. doi: 10.1111/pedi.13426. - DOI - PMC - PubMed
    1. Garcin L, Mericq V, Fauret-Amsellem AL, Cave H, Polak M, Beltrand J. Neonatal diabetes due to potassium channel mutation: Response to sulfonylurea according to the genotype. Pediatr Diabetes. 2020. Sep;21(6):932–941. doi: 10.1111/pedi.13041. Epub 2020 Jul 20. - DOI - PubMed

Publication types